Gilead Sciences Inc (GILD)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 6,085,000 | 5,705,000 | 5,704,000 | 4,936,000 | 5,412,000 | 4,699,000 | 4,739,000 | 4,296,000 | 5,338,000 | 4,362,000 | 4,893,000 | 4,065,000 | 5,997,000 | 12,886,000 | 6,746,000 | 10,051,000 | 11,631,000 | 9,474,000 | 11,240,000 | 16,927,000 |
| Short-term investments | US$ in thousands | 1,179,000 | 1,159,000 | 963,000 | 936,000 | 973,000 | 961,000 | 924,000 | 1,029,000 | 1,182,000 | 1,376,000 | 1,632,000 | 1,601,000 | 1,411,000 | 11,089,000 | 12,168,000 | 10,734,000 | 12,721,000 | 13,382,000 | 15,943,000 | 10,977,000 |
| Receivables | US$ in thousands | 4,660,000 | 4,790,000 | 4,229,000 | 4,162,000 | 4,777,000 | 4,354,000 | 4,118,000 | 3,787,000 | 4,493,000 | 4,566,000 | 4,149,000 | 3,934,000 | 4,901,000 | 3,962,000 | 3,250,000 | 3,967,000 | 3,582,000 | 3,315,000 | 3,396,000 | 3,283,000 |
| Total current liabilities | US$ in thousands | 11,280,000 | 11,945,000 | 13,964,000 | 10,528,000 | 11,237,000 | 10,423,000 | 9,220,000 | 8,558,000 | 11,610,000 | 10,245,000 | 10,214,000 | 9,705,000 | 11,397,000 | 9,509,000 | 10,564,000 | 8,879,000 | 9,759,000 | 9,567,000 | 8,961,000 | 9,397,000 |
| Quick ratio | 1.06 | 0.98 | 0.78 | 0.95 | 0.99 | 0.96 | 1.06 | 1.06 | 0.95 | 1.01 | 1.05 | 0.99 | 1.08 | 2.94 | 2.10 | 2.79 | 2.86 | 2.74 | 3.41 | 3.32 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($6,085,000K
+ $1,179,000K
+ $4,660,000K)
÷ $11,280,000K
= 1.06
The quick ratio of Gilead Sciences, Inc. has shown some fluctuations over the past eight quarters. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations with its most liquid assets.
In Q4 2023, the quick ratio was 1.27, indicating that the company had $1.27 in liquid assets available to cover each dollar of current liabilities. This reflects a slightly improved liquidity position compared to the previous quarter.
Prior to Q4 2023, there were some fluctuations in the quick ratio, with the ratio varying between 0.91 and 1.30. A quick ratio below 1.0 may signify potential liquidity concerns, as it indicates that the company may not be able to meet its short-term obligations using its most liquid assets alone.
It is important to monitor changes in the quick ratio over time to assess Gilead Sciences, Inc.'s ability to manage its short-term financial obligations effectively and maintain a healthy liquidity position.
Peer comparison
Dec 31, 2023